Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Q3 2025 value amounting to $99.8 million.

  • Ultragenyx Pharmaceutical's Shares Outstanding (Weighted Average) rose 447.91% to $99.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $99.8 million, marking a year-over-year increase of 447.91%. This contributed to the annual value of $90.5 million for FY2024, which is 2310.76% up from last year.
  • According to the latest figures from Q3 2025, Ultragenyx Pharmaceutical's Shares Outstanding (Weighted Average) is $99.8 million, which was up 447.91% from $98.5 million recorded in Q2 2025.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Shares Outstanding (Weighted Average) peaked at $99.8 million during Q3 2025, and registered a low of $67.1 million during Q1 2021.
  • Its 5-year average for Shares Outstanding (Weighted Average) is $78.3 million, with a median of $70.9 million in 2023.
  • As far as peak fluctuations go, Ultragenyx Pharmaceutical's Shares Outstanding (Weighted Average) surged by 122.53% in 2023, and later surged by 3325.15% in 2024.
  • Ultragenyx Pharmaceutical's Shares Outstanding (Weighted Average) (Quarter) stood at $67.8 million in 2021, then rose by 3.13% to $69.9 million in 2022, then rose by 5.19% to $73.5 million in 2023, then rose by 23.11% to $90.5 million in 2024, then grew by 10.2% to $99.8 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $99.8 million for Q3 2025, versus $98.5 million for Q2 2025 and $96.3 million for Q1 2025.